BI's Gilotrif is up against some stiff competition in the EGFR lung cancer space. But this week, it snagged a label update that will widen its reach.
Novartis' Kymriah won regulatory milestones from the FDA and EMA as the company works to hold its leadership position in the budding CAR-T field.
While Johnson & Johnson’s multiple myeloma drug Darzalex has steadily won new approvals from the FDA, it continues to face obstacles in England.
One of AbbVie's latest TV ads for IBD awareness doesn't use any words, but that hasn't stopped it from creating controversy.
GSK already partners with Vectura on respiratory therapies, but the British pharma giant could be looking to take the relationship one step further.
Good news for pharma's pricing power: The pitched battle over sticker prices is mostly confined to a few therapeutic areas, a new analysis shows.
Investors worried last year that Merck couldn’t replicate its Keytruda-chemo combo success in a phase 3 trial. But it just did.
McCann Health tapped its first global chief digital officer, highlighting an increase in digital business from pharma clients.
As investigations in the Philippines proceed, Sanofi Pasteur has agreed to refund the cost of unused Dengvaxia doses worth about $28 million.
The risk of biosimilar competition to Roche's top cancer meds prompted one analyst to warn investors to “brace for impact.”